Frontlight ResearchEarly access
Ovarian cancer trials in France
99 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Where
- Angers, Bordeaux, Brest, Marseille, Paris Cedex 13, Toulouse Cedex 9, Villejuif
- Age
- 8 years and over
- People
- 254 worldwide
- Run by
- Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00 - Phase 3Taking peopleAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Where
- Amiens Cedex 1, Avignon Cedex 9, Dax, Nimes Cedex 9, Paris, Pau Cedex, Pierre-Bénite, Plerin, Reims, Saint-Herblain Cedex, Saint-Priest-en-Jarez, Toulouse Cedex 3, Tours Cedex 9
- Age
- 18 years and over
- People
- 1,100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00 - Phase 1Not yet taking people in FranceA Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
- Where
- Bordeaux, Lyon, Villejuif Cedex
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06476808 · EU 2025-523067-38-01 - Phase 1/2Not yet taking people in FranceSafety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer
- Where
- Bordeaux, Caen, Dijon, Lyon, Marseille, Montpellier, Pierre-Bénite, Rennes, Saint-Herblain, Strasbourg, Villejuif
- Age
- 18 years and over
- People
- 43
- Run by
- ARCAGY/ GINECO GROUP
See details and how to joinNCT07637851 · EU 2025-524232-20-00 - Phase 1/2Taking peopleFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Where
- Bordeaux, Lyon, Marseille, Nice Cedex 2, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 880 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00 - Phase 1Taking peopleA Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Where
- Angers, Nice Cedex 2, Poitiers, Vandouvre Les Nancy, Villejuif
- Age
- 18 years and over
- People
- 1,006 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00 - Phase 1/2Taking peopleA phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours
- Where
- Lyon, Villejuif
- Age
- 18 years and over
- People
- 48 worldwide
- Run by
- Apmonia Therapeutics
See details and how to join2025-521164-36-00 - Phase 2CompletedA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- Where
- Nantes Cedex 2, Nice Cedex 2
- Age
- 18 years and over
- People
- 37 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00 - Phase 1Taking peopleStudy of STP938 (Dencatistat) in Advanced Solid Tumours
- Where
- Bordeaux, Nice Cedex 2, Rennes Cedex, Villejuif
- Age
- 18 years and over
- People
- 70 worldwide
- Run by
- Step Pharma, SAS
See details and how to joinNCT06297525 · EU 2024-512375-12-00 - Phase 1/2CompletedA Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Where
- Bayonne, Caen Cedex 5, Lille, Lyon, Marseille, Nice Cedex 2, Paris, St Herblain, Strasbourg, Villejuif
- Age
- 18 years and over
- People
- 182 worldwide
- Run by
- Eisai Inc.
See details and how to joinNCT04300556 · EU 2023-506868-14-00 - Phase 2Taking peopleA Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
- Where
- Caen, La Roche-sur-Yon, Lille, Nice, Paris, Pierre-Bénite, Plérin, Vandœuvre-lès-Nancy
- Age
- 18 years and over
- People
- 110 worldwide
- Run by
- AbbVie
See details and how to joinNCT06682988 · EU 2024-517184-23-00 - No phaseTaking peopleLong-term Ovarian Fertility in Patients Treated for Lymphoma.
- Where
- Lille
- Age
- 18 years to 45 years
- People
- 270
- Run by
- University Hospital, Lille
See details and how to joinNCT05616325 - Phase 2CompletedA basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors
- Where
- Bordeaux, Caen Cedex 5, Clermont-Ferrand, Dijon, Marseille, Paris, Pierre-Bénite, Poitiers
- Age
- 18 years and over
- People
- 101 worldwide
- Run by
- Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.
See details and how to joinNCT05642780 · EU 2022-502654-14-00 - Phase 2Taking peopleAbemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
- Where
- Bordeaux, Lyon, Paris, St Herblain, Strasbourg, Toulouse Cedex 9
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- Universitaire Ziekenhuizen KU Leuven
See details and how to joinNCT05872204 · EU 2023-503533-21-00 - No phaseTaking peopleProspective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma
- Where
- Lyon
- Age
- 18 years and over
- People
- 160
- Run by
- Centre Leon Berard
See details and how to joinNCT04562623 - Phase 2Taking peopleEfficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
- Where
- Bordeaux, Lyon, Paris, Villejuif
- Age
- 18 years and over
- People
- 900
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07303387 - Phase 2Taking peopleNiraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
- Where
- Angers, Avignon, Besancon Cedex, Bordeaux, Brest, Bron, Caen Cedex 5, Cholet, Clermont-Ferrand, Dijon, Grenoble, Grenoble Cedex 9, Le Mans, Lille, Limoges Cedex 1, Lyon, Lyon Cedex 02, Lyon Cedex 04, Marseille, Montpellier, Montpellier Cedex 5, Mougins, Nancy, Nantes Cedex 2, Nimes Cedex 9, Orleans Cedex 2, Paris, Paris Cedex 14, Paris Cedex 20, Plérin, Poitiers, Reims, Rennes Cedex, Rouen, Saint-Herblain, Saint-Priest-en-Jarez, Strasbourg, Toulouse, Tours Cedex 9, Valence, Villejuif
- Age
- 18 years to 99 years
- People
- 390 worldwide
- Run by
- ARCAGY/ GINECO GROUP
See details and how to joinNCT05183984 · EU 2023-504166-37-00 - No phaseTaking peopleProspective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma
- Where
- Lille
- Age
- 18 years and over
- People
- 371
- Run by
- Centre Oscar Lambret
See details and how to joinNCT06969833 - No phaseTaking peoplePrognostic and Predictive Biomarkers in Ovarian Cancers
- Where
- Villejuif
- Age
- 18 years and over
- People
- 350
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT03010124 - Phase 2Taking peopleAssessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
- Where
- Amiens, Caen, Lille
- Age
- 18 years and over
- People
- 88
- Run by
- Centre Oscar Lambret
See details and how to joinNCT05500391 - No phaseNot yet taking people in FranceRisk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer
- Where
- Bordeaux, Caen, Clermont-Ferrand, Dijon, Grenoble, Lille, Lyon, Marseille, Nantes, Nice, Paris, Reims, Rouen, Saint-Cloud, Toulouse, Troyes, Valenciennes
- Age
- 35 years to 50 years
- People
- 1,100
- Run by
- Centre Oscar Lambret
See details and how to joinNCT06726330 - No phaseTaking peopleStudy on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer
- Where
- Amiens, Bron, Clermont-Ferrand, Creil, Dijon, Lyon, Paris, Pierre-Bénite, Rouen, Saint-Grégoire, Saint-Priest-en-Jarez, Valence, Villeurbanne
- Age
- 70 years and over
- People
- 50
- Run by
- Hospices Civils de Lyon
See details and how to joinNCT06572735 - No phaseTaking peopleIdentification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
- Where
- Clermont-Ferrand
- Age
- 18 years and over
- People
- 55
- Run by
- Centre Jean Perrin
See details and how to joinNCT07361471 - No phaseTaking peopleProspective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
- Where
- Bordeaux, Lille, Lyon, Paris, Saint-Cloud, Vandœuvre-lès-Nancy
- Age
- 18 years and over
- People
- 1,050
- Run by
- Institut Curie
See details and how to joinNCT03017573 - No phaseTaking peopleThe Value of the O-RADS Radiological Classification in Predicting the Malignancy of Ovarian Masses in Children
- Where
- Strasbourg
- Age
- 1 year to 16 years
- People
- 100
- Run by
- University Hospital, Strasbourg, France
See details and how to joinNCT07313514